miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer.
Alicia Romero-LorcaApolonia NovilloMaria GaibarMaría Fuencisla GilsanzMiguel GalánLaura BeltránBeatriz AntónDiego MalónAmalia MorenoAna Fernández-SantanderPublished in: Pharmacogenomics and personalized medicine (2021)
High expression values for miR-7-5p and miR-10a-5p might be considered markers of a poorer prognosis in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy, while the same for miR-143-3p might be a marker of better outcomes.